New study aims to cut arthritis flares by tailoring drug tapering

NCT ID NCT06528431

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized approach to slowly reduce the dose of the biologic drug adalimumab in people with rheumatoid arthritis who are in remission. The goal is to find the best blood level of the drug before each dose reduction to lower the risk of disease flares. 180 adults with stable RA will be followed to see if this tailored tapering strategy works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRITIS, RHEUMATOID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTHRITIS, RHEUMATOID

Contacts and locations

Locations

Ap-Hp Pitie Salpetriere
RECRUITING

Paris, 75013, France
Chd Vendee
RECRUITING

La Roche-sur-Yon, 85925, France
Chru Tours
NOT_YET_RECRUITING

Tours, 37170, France
Chu Montpellier
RECRUITING

Montpellier, 34295, France
Chu Reims
NOT_YET_RECRUITING

Reims, 51100, France
Chu Saint Etienne
RECRUITING

Saint-Etienne, 42055, France
Hopital Philibert
RECRUITING

Lomme, 59160, France
Infirmerie Protestante
RECRUITING

Caluire-et-Cuire, 69300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.